Amyloid-Targeting Antibody for Parkinson's Plus Cognitive Decline
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a monoclonal antibody (a type of medicine that targets amyloid, a protein that builds up in the brain) can help people who have both Parkinson's disease and early signs of memory problems or dementia. The study uses brain imaging to confirm amyloid buildup before enrolling patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Parkinson's disease
- Brain imaging (PET scan) shows amyloid protein buildup
- Mild memory problems or early dementia confirmed by cognitive testing
- Age 50–90 years old
- No medical conditions that would prevent you from safely taking lecanemab (the study antibody)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests a monoclonal antibody therapy—a lab-made protein—to see if it can slow Alzheimer's symptoms. You may qualify if you have early Alzheimer's or mild cognitive impairment with a positive PET scan, and you can't have other major health issues like uncontrolled diabetes or heart problems.
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.